Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Apr;77(8):1280–1286. doi: 10.1038/bjc.1998.214

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.

S R Johnston 1, D O Constenla 1, J Moore 1, H Atkinson 1, R P A'Hern 1, G Dadian 1, P G Riches 1, M E Gore 1
PMCID: PMC2150174  PMID: 9579834

Abstract

The purpose of this study was to evaluate in a randomized phase II trial the efficacy and toxicity of combination biochemotherapy compared with chemotherapy alone in patients with metastatic melanoma. Sixty-five patients with metastatic melanoma (ECOG performance status 0 or 1) were randomized to receive intravenous BCNU 100 mg m(-2) (day 1, alternate courses), cisplatin 25 mg m(-2) (days 1-3), DTIC 220 mg m(-2) (days 1-3) and oral tamoxifen 40 mg (BCDT regimen) with (n = 35) or without (n = 30) subcutaneous interleukin 2 (IL-2) 18 x 10(6) iu t.d.s. (day - 2), 9 x 10(6) iu b.d. (day - 1 and 0) and interferon 2 alpha (IFN-alpha) 9 MU (days 1-3). Evidence for immune activation was determined by flow cytometric analysis of peripheral blood lymphocytes. Treatment was repeated every 4 weeks up to six courses depending on response. The overall response rate of BCDT with IL-2/IFN-alpha was 23% [95% confidence interval (CI) 10-40%] with one complete response (CR) and seven partial responses (PR), and for BCDT alone 27% (95% CI 12-46%) with eight PRs; the median durations of response were 2.8 months and 2.5 months respectively. Sites of response were similar in both groups. There was no difference between the two groups in progression-free survival or overall survival (median survival 5 months for BCDT with IL-2/IFNalpha and 5.5 months for BCDT alone). Although 3 days of subcutaneous IL-2 resulted in significant lymphopenia, evidence of immune activation was indicated by a significant rise in the percentage of CD56- (NK cells) and CD3/HLA-DR-positive (activated T cells) subsets, without any change in the percentage of CD4 or CD4 T-cell subsets. Toxicity assessment revealed a significantly higher incidence of severe thrombocytopenia in patients treated with combination chemotherapy than with chemotherapy alone (37% vs 13%, P = 0.03) and a higher incidence of grade 3/4 flu-like symptoms (20% vs 10%) and fatigue (26% vs 13%). The addition of subcutaneous IL-2 and IFNalpha to BCDT chemotherapy in a randomized phase II trial resulted in immune activation but did not improve response rates in patients with metastatic melanoma, and indeed may increase some treatment-related toxicity.

Full text

PDF
1280

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Kirchner H., Körfer A., Hadam M., Schomburg A., Menzel T., Deckert M., Franzke A., Volkenandt M., Dallmann I. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. Tumour Biol. 1993;14(6):354–359. doi: 10.1159/000217850. [DOI] [PubMed] [Google Scholar]
  2. Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990 Jun 23;335(8704):1509–1512. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  3. Atzpodien J., Lopez Hänninen E., Kirchner H., Bodenstein H., Pfreundschuh M., Rebmann U., Metzner B., Illiger H. J., Jakse G., Niesel T. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995 Feb;13(2):497–501. doi: 10.1200/JCO.1995.13.2.497. [DOI] [PubMed] [Google Scholar]
  4. Bajetta E., Di Leo A., Zampino M. G., Sertoli M. R., Comella G., Barduagni M., Giannotti B., Queirolo P., Tribbia G., Bernengo M. G. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol. 1994 Apr;12(4):806–811. doi: 10.1200/JCO.1994.12.4.806. [DOI] [PubMed] [Google Scholar]
  5. Buter J., Sleijfer D. T., van der Graaf W. T., de Vries E. G., Willemse P. H., Mulder N. H. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol. 1993 Dec;20(6 Suppl 9):16–21. [PubMed] [Google Scholar]
  6. Castello G., Comella P., Manzo T., Napolitano M., Parziale A. P., Galati M. G., Daponte A., Casaretti R., Celentano E., Comella G. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res. 1993 Feb;3(1):43–49. doi: 10.1097/00008390-199304000-00007. [DOI] [PubMed] [Google Scholar]
  7. Dadian G., Riches P. G., Henderson D. C., MacLennan K., Lorentzos A., Moore J., Hobbs J. R., Gore M. E. Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol. 1993 Jan;29B(1):29–34. doi: 10.1016/0964-1955(93)90007-2. [DOI] [PubMed] [Google Scholar]
  8. Del Prete S. A., Maurer L. H., O'Donnell J., Forcier R. J., LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep. 1984 Nov;68(11):1403–1405. [PubMed] [Google Scholar]
  9. Demchak P. A., Mier J. W., Robert N. J., O'Brien K., Gould J. A., Atkins M. B. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol. 1991 Oct;9(10):1821–1830. doi: 10.1200/JCO.1991.9.10.1821. [DOI] [PubMed] [Google Scholar]
  10. Dillman R. O., Oldham R. K., Barth N. M., Birch R., Arnold J., West W. H. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst. 1990 Aug 15;82(16):1345–1349. doi: 10.1093/jnci/82.16.1345. [DOI] [PubMed] [Google Scholar]
  11. Falkson C. I., Falkson G., Falkson H. C. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol. 1991 Aug;9(8):1403–1408. doi: 10.1200/JCO.1991.9.8.1403. [DOI] [PubMed] [Google Scholar]
  12. Flaherty L. E., Redman B. G., Chabot G. G., Martino S., Gualdoni S. M., Heilbrun L. K., Valdivieso M., Bradley E. C. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer. 1990 Jun 1;65(11):2471–2477. doi: 10.1002/1097-0142(19900601)65:11<2471::aid-cncr2820651113>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  13. Flaherty L. E., Robinson W., Redman B. G., Gonzalez R., Martino S., Kraut M., Valdivieso M., Rudolph A. R. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer. 1993 Jun 1;71(11):3520–3525. doi: 10.1002/1097-0142(19930601)71:11<3520::aid-cncr2820711110>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  14. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17. doi: 10.1200/JCO.1996.14.1.7. [DOI] [PubMed] [Google Scholar]
  15. Lakhani S., Selby P., Bliss J. M., Perren T. J., Gore M. E., McElwain T. J. Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer. 1990 Feb;61(2):330–334. doi: 10.1038/bjc.1990.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Legha S. S., Buzaid A. C. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol. 1993 Dec;20(6 Suppl 9):27–32. [PubMed] [Google Scholar]
  17. Legha S. S., Ring S., Bedikian A., Plager C., Eton O., Buzaid A. C., Papadopoulos N. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996 Oct;7(8):827–835. doi: 10.1093/oxfordjournals.annonc.a010762. [DOI] [PubMed] [Google Scholar]
  18. Richards J. M., Mehta N., Ramming K., Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992 Aug;10(8):1338–1343. doi: 10.1200/JCO.1992.10.8.1338. [DOI] [PubMed] [Google Scholar]
  19. Rosenberg S. A., Lotze M. T., Yang J. C., Linehan W. M., Seipp C., Calabro S., Karp S. E., Sherry R. M., Steinberg S., White D. E. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989 Dec;7(12):1863–1874. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  20. Rusthoven J. J., Quirt I. C., Iscoe N. A., McCulloch P. B., James K. W., Lohmann R. C., Jensen J., Burdette-Radoux S., Bodurtha A. J., Silver H. K. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996 Jul;14(7):2083–2090. doi: 10.1200/JCO.1996.14.7.2083. [DOI] [PubMed] [Google Scholar]
  21. Sparano J. A., Fisher R. I., Sunderland M., Margolin K., Ernest M. L., Sznol M., Atkins M. B., Dutcher J. P., Micetich K. C., Weiss G. R. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993 Oct;11(10):1969–1977. doi: 10.1200/JCO.1993.11.10.1969. [DOI] [PubMed] [Google Scholar]
  22. Stoter G., Aamdal S., Rodenhuis S., Cleton F. J., Iacobelli S., Franks C. R., Oskam R., Shiloni E. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol. 1991 Sep;9(9):1687–1691. doi: 10.1200/JCO.1991.9.9.1687. [DOI] [PubMed] [Google Scholar]
  23. Thomson D. B., Adena M., McLeod G. R., Hersey P., Gill P. G., Coates A. S., Olver I. N., Kefford R. F., Lowenthal R. M., Beadle G. F. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res. 1993 Apr;3(2):133–138. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES